LBF20303PG05: Difference between revisions
No edit summary |
No edit summary |
||
Line 11: | Line 11: | ||
|Chemical Synthesis= | |Chemical Synthesis= | ||
|Metabolism= | |Metabolism= | ||
|Biological Activity=PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits.[[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]][[Reference:Goh_Y:Nakajima_M:Azuma_I:Hayaishi_O:,Jpn. J. Ophthalmol.,1988,32,471|{{RelationTable/GetFirstAuthor|Reference:Goh_Y:Nakajima_M:Azuma_I:Hayaishi_O:,Jpn. J. Ophthalmol.,1988,32,471}}]][[Reference:Kulkarni_PS:Srinivasan_BD:,Invest. Ophthalmol. Vis. Sci.,1985,26,1178|{{RelationTable/GetFirstAuthor|Reference:Kulkarni_PS:Srinivasan_BD:,Invest. Ophthalmol. Vis. Sci.,1985,26,1178}}]] However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation. | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} |
Revision as of 21:00, 6 January 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1705 |
LipidMaps | LMFA03010142 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20303PG05 |
Prostaglandin D3 | |
---|---|
Structural Information | |
9α,15S-dihydroxy-11-oxo-prosta-5Z,13E,17Z-trien-1-oic acid | |
| |
Formula | C20H30O5 |
Exact Mass | 350.20932407 |
Average Mass | 350.4492 |
SMILES | C(=CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC |
Physicochemical Information | |
PGD3 is produced by the metabolism of EPA via the cyclooxygenase pathway. Kulkarni_PS et al. | |
PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits. Bundy_GL et al. Goh_Y et al. Kulkarni_PS et al. However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|